CN114173827B - 腺相关病毒纯化方法 - Google Patents

腺相关病毒纯化方法 Download PDF

Info

Publication number
CN114173827B
CN114173827B CN202080055070.0A CN202080055070A CN114173827B CN 114173827 B CN114173827 B CN 114173827B CN 202080055070 A CN202080055070 A CN 202080055070A CN 114173827 B CN114173827 B CN 114173827B
Authority
CN
China
Prior art keywords
buffer
certain embodiments
salt
trishcl
polysorbate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080055070.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN114173827A (zh
Inventor
C·菲德勒
M·施耐德
M·哈斯拉赫尔
J·科恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CN114173827A publication Critical patent/CN114173827A/zh
Application granted granted Critical
Publication of CN114173827B publication Critical patent/CN114173827B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/10Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/16Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the fluid carrier
    • B01D15/161Temperature conditioning
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/10Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/20Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804Affinity chromatography
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151Methods of production or purification of viral material
    • C12N2750/14152Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202080055070.0A 2019-06-28 2020-06-26 腺相关病毒纯化方法 Active CN114173827B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962868282P 2019-06-28 2019-06-28
US62/868,282 2019-06-28
PCT/US2020/039971 WO2020264411A1 (en) 2019-06-28 2020-06-26 Adeno-associated virus purification methods

Publications (2)

Publication Number Publication Date
CN114173827A CN114173827A (zh) 2022-03-11
CN114173827B true CN114173827B (zh) 2025-01-28

Family

ID=74061311

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080055070.0A Active CN114173827B (zh) 2019-06-28 2020-06-26 腺相关病毒纯化方法

Country Status (6)

Country Link
US (1) US20220267796A1 (enExample)
EP (1) EP3990031A4 (enExample)
JP (1) JP7539420B2 (enExample)
CN (1) CN114173827B (enExample)
TW (1) TWI886135B (enExample)
WO (1) WO2020264411A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR102198A1 (es) 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica
US11020686B2 (en) 2016-08-16 2021-06-01 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
JP7102401B2 (ja) 2016-10-25 2022-07-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド クロマトグラフィーデータ解析のための方法およびシステム
CA3073935A1 (en) 2017-09-19 2019-03-28 Regeneron Pharmaceuticals, Inc. Methods of reducing particle formation and compositions formed thereby
TWI853823B (zh) 2018-07-02 2024-09-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
EA202192422A1 (ru) 2019-03-05 2021-12-09 Ридженерон Фармасьютикалз, Инк. Человеческий сывороточный альбумин в составах
US20250027855A1 (en) * 2022-01-03 2025-01-23 Kerth Corp. Biological kit for separating electronegative low density lipoprotein from specimen, reagent solution and method for separating electronegative low density lipoprotein from specimen
US20230303983A1 (en) * 2022-03-28 2023-09-28 President And Fellows Of Harvard College High efficiency purification of divergent aav serotypes using aavx affinity chromatography
US20250179442A1 (en) * 2022-03-29 2025-06-05 Kaneka Corporation Method of producing adeno-associated virus
CA3247416A1 (en) * 2022-04-08 2023-10-12 Csl Behring Ag Methods of sanitizing and/or regenerating a chromatography medium
KR20260019635A (ko) * 2023-06-09 2026-02-10 사르토리우스 비아이에이 세퍼레이션스 디.오.오. 완전 충전 아데노 관련 바이러스 (aav) 캡시드의 향상된 분리 방법
EP4731755A2 (en) * 2023-06-23 2026-04-29 Ultragenyx Pharmaceutical Inc. Compositions and methods for reducing host cell proteins in recombinant adeno-associated virus preparations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016128408A1 (en) * 2015-02-09 2016-08-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an affinity purification step

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
IL137510A0 (en) 1998-02-17 2001-07-24 Schering Corp Compositions comprising viruses and methods for concentrating virus preparations
US6593123B1 (en) * 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
US20040106184A1 (en) * 2002-08-28 2004-06-03 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
US20070207461A1 (en) * 2004-02-23 2007-09-06 Crucell Holland B.V. Virus Purification Methods
EP1783138A4 (en) * 2004-07-27 2007-08-22 Genomidea Inc PROCESS FOR PURIFYING A VIRUS ENVELOPE
CN101983238B (zh) * 2008-03-31 2013-06-12 日本烟草产业株式会社 病毒浓缩方法
LT3436051T (lt) * 2016-03-31 2021-11-25 Spark Therapeutics, Inc. Kolonėlėmis pagrįstas visiškai keičiamo masto raav gavimo būdas
EP3731863A4 (en) * 2017-12-29 2021-10-27 Baxalta Incorporated ADENO-ASSOCIATED VIRUS CLEANSING PROCEDURES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016128408A1 (en) * 2015-02-09 2016-08-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an affinity purification step

Also Published As

Publication number Publication date
US20220267796A1 (en) 2022-08-25
JP2022539148A (ja) 2022-09-07
TW202115248A (zh) 2021-04-16
EP3990031A4 (en) 2023-08-09
EP3990031A1 (en) 2022-05-04
CN114173827A (zh) 2022-03-11
WO2020264411A1 (en) 2020-12-30
JP7539420B2 (ja) 2024-08-23
TWI886135B (zh) 2025-06-11

Similar Documents

Publication Publication Date Title
CN114173827B (zh) 腺相关病毒纯化方法
CN111655285B (zh) 腺相关病毒的纯化方法
JP7385603B2 (ja) 組換えaav生成のためのアニオン交換クロマトグラフィー
US20210348133A1 (en) Scalable purification method for aav9
US11015173B2 (en) Scalable purification method for AAV1
US20190002844A1 (en) Scalable purification method for aav8
CN111032176A (zh) Aav载体柱纯化方法
US10626376B2 (en) Method for isolating and purifying adeno-associated virus particles using salt
WO2018128688A1 (en) Adeno-associated virus purification methods
CN108085301B (zh) 从宿主细胞提取和纯化腺相关病毒和腺病毒的方法及其组分和试剂盒
US11193112B2 (en) Scalable process for oncolytic rat parvovirus H-1 production and purification based on isoelectric point-based elimination of empty particles
WO2024252182A1 (en) Cation exchange chromatography for aav capture
CN116867902A (zh) 用于抑制过量核酸沉淀的方法和组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant